 Connection
Brian Freed to Risk Factors
This is a "connection" page, showing publications Brian Freed has written about Risk Factors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.058 |
|
|
|
-
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
Score: 0.015
-
Conti DJ, Shen G, Singh T, Isenberg A, Freed BM. Ganciclovir prophylaxis of cytomegalovirus disease. Transplant Proc. 1997 Feb-Mar; 29(1-2):804-6.
Score: 0.014
-
Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, Cooper JE. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients. Am J Transplant. 2016 12; 16(12):3458-3467.
Score: 0.014
-
Lyu DM, Grazia TJ, Benson AB, Cagle LR, Freed BM, Zamora MR. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients. Clin Transpl. 2012; 237-46.
Score: 0.010
-
Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg. 1994 Apr; 129(4):443-7.
Score: 0.003
-
Conti DJ, Freed BM, Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc. 1993 Feb; 25(1 Pt 2):1421-2.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|